Marcelo Soares: Cytokine and Lymphocyte Profiles of Cancer Patients With COVID-19
Marcelo Soares, Full Investigator at Instituto Nacional do Câncer, Associate Professor at UFRJ, shared a post on LinkedIn about a recent article he and his colleages co-authored, published in Viruses, adding:
“Patients with cancer are at increased risk of severe outcomes from COVID-19, but the immunological determinants underlying this vulnerability remain incompletely understood, particularly in low- and middle-income settings.
This study aimed to characterize the cytokine and lymphocyte profiles of cancer patients with COVID-19, correlate these profiles with disease severity, and compare them to those of non-cancer patients with COVID-19.
A total of 67 patients were analyzed: 40 with cancer (26 mild cases and 14 severe cases) and 27 without cancer (12 mild cases and 15 severe cases).
Our findings revealed elevated CXCL10 (IP-10) and reduced MIF levels in cancer patients with COVID-19, distinguished by disease severity. Compared with that in cancer patients with mild COVID-19, the level of CXCL10 in cancer patients with severe COVID-19 was further elevated.
Additionally, cancer patients with COVID-19 presented reduced CD3+ T lymphocytes, expansion of CD4+CD25+FoxP3+ regulatory cells and CD56BRIGHT NK cells, a shift from effector memory to central memory T-cells, and increased numbers of exhausted (PD-1+) T lymphocytes.
Our data suggest a distinct immunological profile observed in cancer patients with COVID-19, in which viral surge-related suppressor cells and proinflammatory cytokines were accompanied by a compensatory immunosuppressive state, with decreased effector function and increased exhaustion.
I was thrilled to participate in this study led by Joao Viola at INCA and Patricia Bozza at Fundação Oswaldo Cruz (Fiocruz), with participation of our Researcher Livia Goes from Federal University of the State of Rio de Janeiro.”
Title: Cytokine and Lymphocyte Profiles in COVID-19 Patients with Cancer: Implications for Disease Severity and Clinical Outcomes
Authors: Marina M. Burlá, Karina L. Silva, Bárbara C. Peixoto, Livia R. Goes, Isaclaudia Azevedo-Quintanilha, Fernando A. Bozza, Marcelo A. Soares, Andreia C. de Melo, Eugenio D. Hottz, Patricia T. Bozza, João P. B. Viola
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 3, 2026, 19:15Edward Lee Carter: Anticoagulation Drift – The Patient Changes, the Plan Should Too
-
Jul 3, 2026, 19:13Anwar Elshikh: Calciphylaxis and Skin Issues in Renal Failure Patients
-
Jul 3, 2026, 19:11Amr M. Fahmi: Genotype-Guided Warfarin Dosing in the Arab Population
-
Jul 3, 2026, 19:10Isabella Presch: A Step Toward Greater Regulatory Clarity in Genome-Editing Therapeutics
-
Jul 3, 2026, 18:24Alexandros Rampotas: Targeting Mutant CALR With Precision CAR-T Therapy
-
Jul 3, 2026, 18:08Ram Khandelwal: Why AI Is Transforming Patient Education and the Future of Healthcare
-
Jul 3, 2026, 17:55Miguel Bronchud: Why Congenital Neutropenia Is Often Missed
-
Jul 3, 2026, 17:35Patrick Rensen: Celebrating 25 Years in Endocrinology at Leiden University Medical Center
-
Jul 3, 2026, 16:54Alberico Catapano: The Role of Triglyceride Variability and the AIFA Reimbursement Gap